Skip to main content
Top
Published in: Clinical Rheumatology 11/2016

01-11-2016 | Original Article

Anti-MCV and anti-CCP antibodies—diagnostic and prognostic value in children with juvenile idiopathic arthritis (JIA)

Authors: Joanna Lipinska, Stanislawa Lipinska, Marek Kasielski, Elzbieta Smolewska

Published in: Clinical Rheumatology | Issue 11/2016

Login to get access

Abstract

The goal of the study was to evaluate the diagnostic and prognostic value of anti-mutated citrullinated vimentin (anti-MCV) antibodies in juvenile idiopathic arthritis (JIA) comparing to anti-cyclic citrullinated peptide (anti-CCP). Thirty children with confirmed JIA diagnosis and 20 children as a control group were included into the study. Serum and synovial fluid levels of anti-CCP, anti-MCV, and immunoglobulin M rheumatoid factor (IgM-RF) antibodies have been assessed. Anti-MCV was positive in 11/30 (36.6 %), whereas anti-CCP positivity was found in 12/30 (40 %) children with JIA. Among 11 children with JIA positive for anti-MCV, five (45.5 %) were also positive for anti-CCP and among 18 JIA children negative for anti-CCP, six (33.33 %) were also anti-MCV positive. Six out of 30 JIA children were found to be IgM-RF positive. In general, two out of all those 11 anti-MCV-positive patients demonstrated oligoarthritis and 9/11 had polyarticular type of onset. Anti-MCV serum concentration correlated positively with anti-CCP (p = 0.004). Almost 60 % of children in early stage of JIA were anti-MCV positive. Levels of anti-CCP antibodies correlated positively with the disease activity (p = 0.0014) and radiological outcome (p = 0.00017). In all synovial fluid samples, the concentration of autoantibodies was under the cut-off values. The results of our study indicate that anti-MCV as well as anti-CCP antibodies may be helpful in the diagnosis of JIA, especially in the early course of the disease. Anti-MCV antibodies could identify a group of children with JIA which is negative for anti-CCP antibodies and RF. However, it appears that in JIA, anti-CCP rather than anti-MCV antibodies have impact on radiographic changes.
Literature
1.
go back to reference Cassidy JT, Lindsley CB (2005) Chronic arthritis in childhood. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB (eds) Textbook of pediatric rheumatology. Elsevier Saunders, Philadelphia, pp. 206–260CrossRef Cassidy JT, Lindsley CB (2005) Chronic arthritis in childhood. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB (eds) Textbook of pediatric rheumatology. Elsevier Saunders, Philadelphia, pp. 206–260CrossRef
3.
go back to reference Martini A, Lovell DJ (2010) Juvenile idiopathic arthritis: state of the art and future perspectives. Ann Rheum Dis 69:1260–1263CrossRefPubMed Martini A, Lovell DJ (2010) Juvenile idiopathic arthritis: state of the art and future perspectives. Ann Rheum Dis 69:1260–1263CrossRefPubMed
4.
go back to reference Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, International League of Associations for Rheumatology, et al. (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31:390–392PubMed Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, International League of Associations for Rheumatology, et al. (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31:390–392PubMed
5.
go back to reference Luime JJ, Colin EM, Hazes JM, Lubberts E (2010) Does anti-mutated citrullinated vimentin have additional value as a serological marker in the diagnostic and prognostic investigation of patients with rheumatoid arthritis? A systematic review. Ann Rheum Dis 69(2):337–344CrossRefPubMed Luime JJ, Colin EM, Hazes JM, Lubberts E (2010) Does anti-mutated citrullinated vimentin have additional value as a serological marker in the diagnostic and prognostic investigation of patients with rheumatoid arthritis? A systematic review. Ann Rheum Dis 69(2):337–344CrossRefPubMed
6.
go back to reference Kuna AT (2012) Mutated citrullinated vimentin antibodies in rheumatoid arthritis. Clin Chim Acta 413(1–2):66–73CrossRefPubMed Kuna AT (2012) Mutated citrullinated vimentin antibodies in rheumatoid arthritis. Clin Chim Acta 413(1–2):66–73CrossRefPubMed
7.
go back to reference Turesson C, Mathsson L, Jacobsson LT, Sturfelt G, Rönnelid J (2013) Antibodies to modified citrullinated vimentin are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis 72(12):2047–2048CrossRefPubMed Turesson C, Mathsson L, Jacobsson LT, Sturfelt G, Rönnelid J (2013) Antibodies to modified citrullinated vimentin are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis 72(12):2047–2048CrossRefPubMed
8.
go back to reference Nicaise-Roland P, Nogueira L, Demattei C, de Chaisemartin L, Rincheval N, Cornillet M, et al. (2013) Autoantibodies to citrullinated fibrinogen compared with anti-MCV and anti-CCP2 antibodies in diagnosing rheumatoid arthritis at an early stage: data from the French ESPOIR cohort. Ann Rheum Dis 72(3):357–362CrossRefPubMed Nicaise-Roland P, Nogueira L, Demattei C, de Chaisemartin L, Rincheval N, Cornillet M, et al. (2013) Autoantibodies to citrullinated fibrinogen compared with anti-MCV and anti-CCP2 antibodies in diagnosing rheumatoid arthritis at an early stage: data from the French ESPOIR cohort. Ann Rheum Dis 72(3):357–362CrossRefPubMed
9.
go back to reference Avdeeva AS, Aleksandrova EN, Novikov AA, Smirnov AV, Cherkasova MV, Nasonov EL. The relationship of antibodies to modified citrullinated vimentin and markers of bone and cartilage destruction in rheumatoid arthritis. Int J Rheumatol 2014;2014:464585. Avdeeva AS, Aleksandrova EN, Novikov AA, Smirnov AV, Cherkasova MV, Nasonov EL. The relationship of antibodies to modified citrullinated vimentin and markers of bone and cartilage destruction in rheumatoid arthritis. Int J Rheumatol 2014;2014:464585.
10.
go back to reference Derganova O, Martinez-Gamboa L, Egerer K, Bang H, Fredenhagen G, Roggenbuck D, et al. (2014) Selected cyclic citrullinated peptides derived from the sequence of mutated and citrullinated vimentin (MCV) are targeted by different antibodies subclasses in patients with rheumatoid arthritis in Russian patients. Clin Exp Rheumatol 32(5):622–629PubMed Derganova O, Martinez-Gamboa L, Egerer K, Bang H, Fredenhagen G, Roggenbuck D, et al. (2014) Selected cyclic citrullinated peptides derived from the sequence of mutated and citrullinated vimentin (MCV) are targeted by different antibodies subclasses in patients with rheumatoid arthritis in Russian patients. Clin Exp Rheumatol 32(5):622–629PubMed
11.
go back to reference Díaz-Toscano ML, Olivas-Flores EM, Zavaleta-Muñiz SA, Gamez-Nava JI, Cardona-Muñoz EG, Ponce-Guarneros M, et al. (2014) Comparison of two assays to determine anti-citrullinated peptide antibodies in rheumatoid arthritis in relation to other chronic inflammatory rheumatic diseases: assaying anti-modified citrullinated vimentin antibodies adds value to second-generation anti-citrullinated cyclic peptides testing. Biomed Res Int 2014:198198CrossRefPubMedPubMedCentral Díaz-Toscano ML, Olivas-Flores EM, Zavaleta-Muñiz SA, Gamez-Nava JI, Cardona-Muñoz EG, Ponce-Guarneros M, et al. (2014) Comparison of two assays to determine anti-citrullinated peptide antibodies in rheumatoid arthritis in relation to other chronic inflammatory rheumatic diseases: assaying anti-modified citrullinated vimentin antibodies adds value to second-generation anti-citrullinated cyclic peptides testing. Biomed Res Int 2014:198198CrossRefPubMedPubMedCentral
12.
go back to reference Reyes-Castillo Z, Palafox-Sánchez CA, Parra-Rojas I, Martínez-Bonilla GE, Del Toro-Arreola S, Ramírez-Dueñas MG, et al. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features. Clin Exp Immunol 2015;182(2):119–131. Reyes-Castillo Z, Palafox-Sánchez CA, Parra-Rojas I, Martínez-Bonilla GE, Del Toro-Arreola S, Ramírez-Dueñas MG, et al. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features. Clin Exp Immunol 2015;182(2):119–131.
13.
go back to reference Lipinska J, Brózik H, Stanczyk J, Smolewska E (2012) Anticitrullinated protein antibodies and radiological progression in juvenile idiopathic arthritis. J Rheumatol 39(5):1078–1087CrossRefPubMed Lipinska J, Brózik H, Stanczyk J, Smolewska E (2012) Anticitrullinated protein antibodies and radiological progression in juvenile idiopathic arthritis. J Rheumatol 39(5):1078–1087CrossRefPubMed
14.
go back to reference Tebo AE, Jaskowski T, Davis KW, Whiting A, Clifford B, Zeft A, et al. (2012) Profiling anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis. Pediatr Rheumatol Online J 10(1):29CrossRefPubMedPubMedCentral Tebo AE, Jaskowski T, Davis KW, Whiting A, Clifford B, Zeft A, et al. (2012) Profiling anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis. Pediatr Rheumatol Online J 10(1):29CrossRefPubMedPubMedCentral
15.
go back to reference Omar A, Abo-Elyoun I, Hussein H, Nabih M, Atwa H, Gad S, et al. (2013) Anti-cyclic citrullinated peptide (anti-CCP) antibody in juvenile idiopathic arthritis (JIA): correlations with disease activity and severity of joint damage (a multicenter trial). Joint Bone Spine 80(1):38–43CrossRefPubMed Omar A, Abo-Elyoun I, Hussein H, Nabih M, Atwa H, Gad S, et al. (2013) Anti-cyclic citrullinated peptide (anti-CCP) antibody in juvenile idiopathic arthritis (JIA): correlations with disease activity and severity of joint damage (a multicenter trial). Joint Bone Spine 80(1):38–43CrossRefPubMed
16.
go back to reference Guseinova D, Lazareva A, Shantere R, Berzinja D, Rasnachs O, Stanevicha V (2008) The value of antibodies against mutated citrullinated vimentin in juvenile idiopathic arthritis. Pediatr Rheumatol Online J 6(Suppl 1):P67CrossRefPubMedCentral Guseinova D, Lazareva A, Shantere R, Berzinja D, Rasnachs O, Stanevicha V (2008) The value of antibodies against mutated citrullinated vimentin in juvenile idiopathic arthritis. Pediatr Rheumatol Online J 6(Suppl 1):P67CrossRefPubMedCentral
17.
go back to reference Kuna AT, Lamot L, Miler M, Harjacek M, Simundic AM, Vrkic N (2009) Antibodies to mutated citrullinated vimentin and antibodies to cyclic citrullinated peptides in juvenile idiopathic arthritis. Clin Chem Lab Med 47(12):1525–1530CrossRefPubMed Kuna AT, Lamot L, Miler M, Harjacek M, Simundic AM, Vrkic N (2009) Antibodies to mutated citrullinated vimentin and antibodies to cyclic citrullinated peptides in juvenile idiopathic arthritis. Clin Chem Lab Med 47(12):1525–1530CrossRefPubMed
18.
go back to reference Morbach H, Dannecker H, Kerkau T, Girschick HJ (2010) Prevalence of antibodies against mutated citrullinated vimentin and cyclic citrullinated peptide in children with juvenile idiopathic arthritis. Clin Exp Rheumatol 28(5):800PubMed Morbach H, Dannecker H, Kerkau T, Girschick HJ (2010) Prevalence of antibodies against mutated citrullinated vimentin and cyclic citrullinated peptide in children with juvenile idiopathic arthritis. Clin Exp Rheumatol 28(5):800PubMed
19.
go back to reference Gilliam BE, Chauhan AK, Moore TL (2013) Evaluation of anti-citrullinated type II collagen and anti-citrullinated vimentin antibodies in patients with juvenile idiopathic arthritis. Pediatr Rheumatol Online J 11(1):31CrossRefPubMedPubMedCentral Gilliam BE, Chauhan AK, Moore TL (2013) Evaluation of anti-citrullinated type II collagen and anti-citrullinated vimentin antibodies in patients with juvenile idiopathic arthritis. Pediatr Rheumatol Online J 11(1):31CrossRefPubMedPubMedCentral
20.
go back to reference Bulatović Calasan M, de Vries LD, Vastert SJ, Heijstek MW, Wulffraat NM (2014) Interpretation of the Juvenile Arthritis Disease Activity Score: responsiveness, clinically important differences and levels of disease activity in prospective cohorts of patients with juvenile idiopathic arthritis. Rheumatology (Oxford) 53(2):307–312CrossRef Bulatović Calasan M, de Vries LD, Vastert SJ, Heijstek MW, Wulffraat NM (2014) Interpretation of the Juvenile Arthritis Disease Activity Score: responsiveness, clinically important differences and levels of disease activity in prospective cohorts of patients with juvenile idiopathic arthritis. Rheumatology (Oxford) 53(2):307–312CrossRef
21.
go back to reference Viola S, Felici E, Magni-Manzoni S, Pistorio A, Buoncompagni A, Ruperto N, et al. (2005) Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. Arthritis Rheum 52(7):2092–2102CrossRefPubMed Viola S, Felici E, Magni-Manzoni S, Pistorio A, Buoncompagni A, Ruperto N, et al. (2005) Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. Arthritis Rheum 52(7):2092–2102CrossRefPubMed
22.
go back to reference Bartoloni E, Alunno A, Bistoni O, Bizzaro N, Migliorini P, Morozzi G, Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA) investigators, et al. (2012) Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature. Autoimmun Rev 11(11):815–820CrossRefPubMed Bartoloni E, Alunno A, Bistoni O, Bizzaro N, Migliorini P, Morozzi G, Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA) investigators, et al. (2012) Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature. Autoimmun Rev 11(11):815–820CrossRefPubMed
23.
go back to reference Fabris M, De Vita S, Blasone N, Visentini D, Pezzarini E, Pontarini E, et al. (2010) Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab. Auto Immun Highlights 1(2):87–94CrossRefPubMedPubMedCentral Fabris M, De Vita S, Blasone N, Visentini D, Pezzarini E, Pontarini E, et al. (2010) Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab. Auto Immun Highlights 1(2):87–94CrossRefPubMedPubMedCentral
24.
go back to reference Koivula MK, Heliövaara M, Rissanen H, Palosuo T, Knekt P, Immonen H, et al. (2012) Antibodies binding to citrullinated telopeptides of type I and type II collagens and to mutated citrullinated vimentin synergistically predict the development of seropositive rheumatoid arthritis. Ann Rheum Dis 71(10):1666–1670CrossRefPubMed Koivula MK, Heliövaara M, Rissanen H, Palosuo T, Knekt P, Immonen H, et al. (2012) Antibodies binding to citrullinated telopeptides of type I and type II collagens and to mutated citrullinated vimentin synergistically predict the development of seropositive rheumatoid arthritis. Ann Rheum Dis 71(10):1666–1670CrossRefPubMed
25.
go back to reference Ferraccioli G, Tolusso B, Bobbio-Pallavicini F, Gremese E, Ravagnani V, Benucci M, et al. (2012) Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis. PLoS One 7(7):e40362CrossRefPubMedPubMedCentral Ferraccioli G, Tolusso B, Bobbio-Pallavicini F, Gremese E, Ravagnani V, Benucci M, et al. (2012) Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis. PLoS One 7(7):e40362CrossRefPubMedPubMedCentral
26.
go back to reference Reis J, Aguiar F, Brito I (2016) Anti CD20 (rituximab) therapy in refractory pediatric rheumatic diseases. Acta Reumatol Port 41(1):45–55 Reis J, Aguiar F, Brito I (2016) Anti CD20 (rituximab) therapy in refractory pediatric rheumatic diseases. Acta Reumatol Port 41(1):45–55
Metadata
Title
Anti-MCV and anti-CCP antibodies—diagnostic and prognostic value in children with juvenile idiopathic arthritis (JIA)
Authors
Joanna Lipinska
Stanislawa Lipinska
Marek Kasielski
Elzbieta Smolewska
Publication date
01-11-2016
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 11/2016
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-016-3355-1

Other articles of this Issue 11/2016

Clinical Rheumatology 11/2016 Go to the issue